期刊文献+

吸入给药的剂型选择和等效性验证 被引量:8

Selection of dosage form and evaluation of therapeutic equivalence for inhaled medical products
下载PDF
导出
摘要 目前临床常用吸入给药的剂型包括定量吸入气雾剂(metered dose inhaler,MDI)、吸入粉雾剂/干粉吸入剂(Dry powder inhaler,DPI)和吸入喷雾剂(Nebulizer),这3种吸入给药剂型各有特点。如何正确选择所研发的药物的剂型,如何正确验证相同制剂间是否等效有其特殊性。本文结合吸入给药的药物吸收特点、各剂型特点及国外有关考虑,重点探讨了如何正确选择所研发的药物的剂型及如何正确验证相同制剂间是否等效。 The dosage forms of inhaled drugs include metered dose inhaler (MDI) , dry powder inhaler (DPI) and nebulizer. These dosage forms have different properties. In selecting a dosage form, the absorption of inhaled drugs is especially important. In this article, we focus on the development of dosage forms, and on the validation of therapeutic equivalence for the same medical products.
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第5期433-436,共4页 Chinese Journal of New Drugs
关键词 吸入给药 吸入气雾剂 吸入粉雾剂 吸入喷雾剂 生物等效 inhaler metered dose inhaler dry powder inhaler nebulizer bioequivalence
  • 相关文献

参考文献14

  • 1金方,施丽西,陆敏,谢保源.吸入剂有效部位药物沉积量试验方法的研究[J].中国药学杂志,1999,34(10):672-674. 被引量:5
  • 2DERENDORF H, HOCHHAUS G, MOLLMANN H. Evaluation of pulmonary absorption using pharmacokinetic methods [ J]. J Aerosol Med, 2001, 14( Suppl 1 ) :S9 - S17.
  • 3LOTVALL J. Local versus systemic effects of inhaled drugs[J]. Respir Med, 1997, 91 ( Suppl A) :29 - 31.
  • 4LIPWORTH BJ. Pharmacokinetics of inhaled drugs [ J]. Br J Clin Pharmacol, 1996, 42 (6) :697 - 705.
  • 5NEWMAN SP, WILDING IR, HIRST PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? [ J ]. Int J Pharm,2000, 208 (N1-2) : 49 - 60.
  • 6LABIRIS NR, DOLOVICH MB. Pulmonary drug delivery. Part Ⅱ: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications[J]. BrJ Clin Pharmacol, 2003, 56 (6) :600 - 612.
  • 7DALBY R, SUMAN J. Inhalation therapy: technological milestones in asthma treatment [ J ]. Adv Drug Dellv Rev, 2003, 55 (7) :779 -791.
  • 8BARRY PW, O'CALLAGHAN C. The influence of inhaler selection on efficacy of asthma therapies [ J ]. Adv Drug Deliv Rev, 2003, 55(7) :879 -923.
  • 9美国食品药品监督管理局.Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action [ J/ OL]. ( 2003 - 04 - 02 ). http ://www. fda. gov/cder/guidance.
  • 10欧洲药品评价局.Points to consider on the requirement for clinical documentation for metered dose inhalers (MDI) [ J/OL]. (2002 -01 - 17 ). http://www. emea. eu. int.

共引文献4

同被引文献93

  • 1胡成平.吸入性糖皮质激素与长效β_2-受体激动剂联合应用治疗哮喘的原则[J].中国实用内科杂志,2007,27(4):262-264. 被引量:30
  • 2陈桂良,侯惠民.吸入用气雾剂雾粒测定方法的评价[J].中国医药工业杂志,2007,38(3):194-199. 被引量:24
  • 3刘素英,冯素香,黄国稠,李小青.高效液相色谱法测定盐酸溴己新片的含量[J].广东药学院学报,2007,23(2):162-163. 被引量:9
  • 4Laube BL, Janssens HM, de Jongh FH, et al. What thepulmonary specialist should know about the new inhalationtherapies. ERS/ISAM task force report [J]. Eur Respir J,2011,37(6):1308-1331.
  • 5金方、侯曙光译,呼吸道药物递送的基本理论与实践[M].北京:化学工业出版社,2011: 222-223.
  • 6Clarke MJ, Bynm J,Taniforth N. Physicochemical factorsgoverning the performance of nedocromil sodium as a powderaerosol[J]. J Pharm Sci, 2000,89(9):1160-1169.
  • 7郑昕,LouiseR,陈昱,等.含福莫特罗的MDI的研究进展[J].国际医药商情,2012,12:28-30.
  • 8Cazzola M, Spina D, Matera MG. The use of bronchodilatorsin stable chronic obstructive pulmonary disease[J]. PulmPharmaco Ther, 1997,10(3):129-144.
  • 9Laforce C, Aunlann J, de Teresa Parrefiol, et al. Sustained 24-hour efficacy of once daily indacaterol(300mug)in patientswith chronic obstructive pulmonary disease: A randomized,crossover study[J]. Pulm Pharmaco Ther, 2011, 24(1):162-168.
  • 10Vail Ncord J, Smeets J, Drenth B, et al. 24-hour bronchodilationfollowing a single dose of the novel beta 2-agonist oiodatcrol inCOPD[J]. Pulm Pharmaco Ther, 2011, 24(6):666-672.

引证文献8

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部